AKTS (Aktis Oncology, Inc.) Stock Financials & Earnings

AKTSAktis Oncology, Inc.

Mkt Cap$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$933,000

Net Income (TTM)-$12M

EPS (TTM)$0.00

Free Cash Flow (TTM)-$15M

Gross Margin100.0%

Op. Margin-1675.8%

Net Margin-1292.2%

FCF Margin-1610.7%

P/S Ratio (TTM)1091.5x

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 24	$933K	$933K	-$16M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 24	-$13M	-$15M

Capital Expenditures

CapEx

Quarter	CapEx
Q4 24	$2M

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 24	$1M	113.0%

OpEx Breakdown

Quarter	R&D	G&A
Q4 24	$13M	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q3 24	$225M	$88M	$312M
Q4 24	$37M	$260M	$297M
Q3 25	$180M	$66M	$246M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 24	0	—